Advertisement
News
Advertisement

Bristol combination diabetes drug under review

Wed, 03/17/2010 - 6:17am
The Associated Press

Bristol-Myers Squibb Co. and AstraZeneca said Wednesday the Food and Drug Administration is reviewing their application for fixed dose of Onglyza in combination with metformin as a treatment for diabetes.

Onglyza, made by Bristol-Myers and AstraZeneca, is already approved as a diabetes treatment and metformin is a widely-used generic diabetes pill.

The company did not provide an estimate for an FDA decision.

Advertisement
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading